Tiverton Asset Management LLC lifted its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,178 shares of the biotechnology company’s stock after buying an additional 1,664 shares during the quarter. Tiverton Asset Management LLC owned approximately 0.06% of bluebird bio worth $3,065,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently bought and sold shares of BLUE. Bank of Montreal Can grew its position in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares in the last quarter. Turner Investments LLC bought a new position in shares of bluebird bio during the 2nd quarter worth $184,000. SG Americas Securities LLC grew its position in shares of bluebird bio by 17.9% during the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after buying an additional 295 shares in the last quarter. Affinity Investment Advisors LLC bought a new position in shares of bluebird bio during the 2nd quarter worth $246,000. Finally, Berkeley Capital Partners LLC bought a new position in shares of bluebird bio during the 1st quarter worth $282,000.
bluebird bio, Inc. (BLUE) traded down 0.19% during midday trading on Friday, reaching $131.60. The company’s stock had a trading volume of 1,127,989 shares. The firm’s market capitalization is $6.00 billion. The stock’s 50-day moving average price is $106.30 and its 200 day moving average price is $96.34. bluebird bio, Inc. has a 1-year low of $37.05 and a 1-year high of $136.85.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company’s revenue was up 977.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.59) earnings per share. Equities analysts anticipate that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.
A number of equities analysts have recently issued reports on the company. BTIG Research reissued a “buy” rating and set a $112.00 price target on shares of bluebird bio in a research report on Thursday, June 1st. Zacks Investment Research downgraded bluebird bio from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BidaskClub downgraded bluebird bio from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC reissued a “buy” rating and set a $88.00 price target on shares of bluebird bio in a research report on Friday, August 11th. Finally, Maxim Group raised bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $107.86.
In other news, insider Nick Leschly sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 27th. The stock was sold at an average price of $108.05, for a total transaction of $2,701,250.00. Following the completion of the transaction, the insider now directly owns 360,656 shares of the company’s stock, valued at approximately $38,968,880.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Daniel Lynch sold 4,000 shares of the company’s stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $109.09, for a total value of $436,360.00. Following the transaction, the director now directly owns 4,808 shares of the company’s stock, valued at $524,504.72. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 153,248 shares of company stock valued at $17,708,425. Insiders own 3.90% of the company’s stock.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.